The effects of statins on microglial cells to protect against neurodegenerative disorders: A mechanistic review
AbstractMicroglia are the primary innate immune system cells in the central nervous system (CNS). They are crucial for the immunity, neurogenesis, synaptogenesis, neurotrophic support, phagocytosis of cellular debris, and maintaining the CNS integrity and homeostasis. Invasion by pathogens as well as in CNS injuries and damages results in activation of microglia known as microgliosis. The activated microglia have the capacity to release proinflammatory mediators leading to neuroinflammation. However, uncontrolled neuroinflammation can give rise to various neurological disorders (NDs), especially the neurodegenerative diseases including Parkinson's disease (PD) and related disorders, Alzheimer's disease (AD) and other dementias, multiple sclerosis (MS), Huntington's disease (HD), spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), and stroke. Statins (HMG ‐CoA reductase inhibitors) are among the most widely prescribed medications for the management of hypercholesterolemia worldwide. It can be used for primary prevention in healthy individuals who are at higher risk of cardiovascular and coronary heart diseases as well as the secondary prevention in patients with cardiovascular and coronary heart diseases disease. A growing body of evidence has indicated that statins have the potential to attenuate the proinflammatory mediators and subsequent NDs by controlling the microglial activation and consequent reduction in neuroinflammator...
ConclusionsBy using PIM-Check in geriatric settings, some PIP will not be detected. It is considered as a limitation for this tool in this frail population but brings a certain complementarity in other areas of therapy not covered by STOPP/START.
AbstractTrazodone is a widely used antidepressant that is also useful in the control of agitation and insomnia in Alzheimer's disease. This drug is now recognized as having a new mechanism of action, an effect on the unfolded protein response (UPR) pathway, restoring protein translation and slowing neurodegenerative progression in mice. This mechanism may have a role in dementia-modifying treatment. To explore the effects of trazodone on human cognition and to search for clinical evidence of its putative benefits in human neurodegenerative diseases, a systematic review was conducted for studies that evaluated the eff...
In stable patients with COVID-19, use of aspirin or apixaban did not reduce the rate of the composite of all-cause mortality, thromboembolism, MI, stroke, or hospitalization in the ACTIV-4B trial.Medscape Medical News
The drug, Aduhelm, brought in $300,000 in revenue in its first full three months of availability. The company expects the drug to generate minimal revenue for the rest of the year.
Condition: Stroke Interventions: Combination Product: Action observation treatment; Combination Product: conventional treatment Sponsor: Riphah International University Completed
Condition: Stroke Intervention: Behavioral: Kinematic movement analysis Sponsors: Norwegian University of Science and Technology; St. Olavs Hospital; OsloMet Not yet recruiting
Conditions: Visual Field Defect, Peripheral; Stroke; Visual Impairment; Hemianopsia Interventions: Device: transcranial random noise stimulation (tRNS); Behavioral: Computer Based Visual Training; Device: Sham stimulation Sponsor: Beth Israel Deaconess Medical Center Not yet recruiting
Stroke is the fifth leading cause of death in the United States and is a leading cause of disability. Extracranial internal carotid artery stenosis is a major cause of ischemic stroke, as it is estimated to cause 8% to 15% of ischemic strokes. It is critical to improve our strategies for stroke prevention and treatment in order to reduce the burden of this disease. Herein, we review approaches for the diagnosis and risk stratification of carotid artery disease as well as interventional strategies for the prevention and treatment of strokes caused by carotid artery disease.
This article is categorized under: Neurological Diseases> Biomedical Engineering Neurological Diseases> Molecular and Cellular Physiology Neurological Diseases> Stem Cells and Development
Would that the popular media produced more popular science articles about the longevity industry like this one. It is not just a profile of someone trying to make a difference in the world by advancing the state of medicine, but also a look at some of the companies and ventures involved in that process. And all that while being a sober consideration of the potential to bring aging under medical control, and thereby end some of the largest causes of suffering and death in late life. Michael Greve thought to himself: It would be stupid to kick the bucket now. He started to look into nutrition, gave up coke, pizza, a...